KEYWORDS cerebral infarction; emergency medicine; plasminogen activators; thrombolytic therapy Background/Purpose: Explaining the risks and benefits of recombinant tissue-plasminogen activator (rtPA) to eligible patients with acute ischemic stroke (AIS) within a few minutes is important but difficult. We examined whether a new thrombolysis program can decrease the door-to-needle (DTN) time when treating patients with AIS. Methods: A new rtPA thrombolysis program with video assistance was adapted for patients with AIS and their families. We retrospectively compared outcome quality before (2009e2011) and after (2012) the program began. Outcomes included DTN time, the percentage of rtPA thrombolysis within 3 hours of onset in all hospitalized patients with AIS who presented within 2 hours of onset (2hr%) and the percentage of rtPA thrombolysis in all hospitalized patients with AIS (AIS%). Results: We recruited patients with AIS who had undergone thrombolytic therapy before (n Z 18) and after (n Z 14) the initiation of the new program. DTN time decreased (93 AE 24 minutes to 57 AE 14 minutes, p < 0.001) and the AIS% increased (2% to 5%, p Z 0.010) after the program. The 2hr% marginally significantly increased (18% to 33%, p Z 0.080).
Introduction
Recombinant tissue-type plasminogen activator (rtPA) is the only approved effective thrombolytic agent for acute ischemic stroke (AIS). When administered intravenously within 3 hours of symptom onset, rtPA increases by at least 33% the chance of functional independence within 3 months, but also increases by at least 1000% the risk of intracerebral hemorrhage (ICH) for patients with AIS. 1 The narrow window of treatment time and the potential risk of ICH when using rtPA has substantially limited the use of this treatment. 2 The Taiwan Stroke Registry shows that from 2006 through 2008, only approximately 1.5% of all hospitalized patients with AIS and 8.8% of those who presented within 2 hours of symptom onset were given intravenous (IV) rtPA. 3 In Taiwan and other countries, informed consent must be obtained before thrombolytic therapy is instituted. Because stroke is an acute and serious neurologic disorder, it may be difficult for physicians to explain the risks and benefits of rtPA to patients or their surrogates in an emergency. Visual analogues such as figures and outcome wheels have been used to convey such important information about rtPA to those for whom it is potentially warranted. 4, 5 However, the effect of these methods of communication has been insufficiently studied, especially in community hospitals. In the current study, we compared the effect of a thrombolysis program with video-assisted therapeutic risk communication on the improvement of the quality of care for patients with AIS.
Patients and methods

Hospital setting
The Tainan Sin Lau hospital (SLH; Tainan, Taiwan) is a community regional teaching hospital and a secondary referral center in the East District of Tainan City. SLH has 285 acute beds, with an average of 273 hospitalized patients per day in 2012. Three board-certified neurologists see approximately 300 patients with AIS per year.
Thrombolytic program
SLH set up its own primary stroke center in 2009 and provided thrombolytic therapy 24 hours a day, 7 days a week for indicated patients with AIS who presented within 3 hours of symptom onset. The Taiwan Department of Health accredited the SLH Stroke Center to perform stroke thrombolysis in 2011. We followed the treatment guidelines of the Taiwan Stroke Society 6 when selecting patients eligible for rtPA. If eligible, patients with AIS are treated with an IV dosage of 0.9 mg rtPA/kg of body weight. 7 The initial 10% of the rtPA was administered with an IV bolus injection within 1 minute, whereas the other 90% was administered via IV drip for 1 hour. 7 Because treatment initiation time was critical and limited, we accepted from the patient or the patient's surrogate an oral statement of the patient's body weight to calculate the required dose of rtPA.
From 2012, several new strategies have been implemented to reduce DTN time. For example, the computed tomography (CT) room has been moved from the first basement level to the first floor to reduce the delay in diagnostic imaging. In addition, a special plastic bag is now used when transferring blood samples to indicate that the blood tests should be done as soon as possible. A new thrombolysis program with video-assisted therapeutic risk communication has also been initiated. Briefly, all patients with hyperacute stroke who are potentially eligible for rtPA and their family are shown a 5-minute animated video. The content of the video is now available online (www.stroke. org.tw). It simply illustrates the pathophysiology of AIS, the mechanism of rtPA to dissolve the thrombus, and the overall risks and benefits of the treatment. This video is usually shown while the patient is waiting for an emergency brain CT or an evaluation by the neurologist on duty. After they have watched the video, the patient and family members can direct questions about the procedure to the emergency physician or neurologist on duty. After obtaining an evaluation of the patient and the informed consent of the patient or surrogate, the neurologist on duty makes the final decision on patient eligibility for rtPA treatment.
Study design
This retrospective study used preexisting stroke registry materials. SLH started to register patients hospitalized with AIS in 2009 based on the format of the Taiwan Stroke Registry (TSR). To assess the video-assisted thrombolytic program's effectiveness, all patients with AIS who underwent intravenous rtPA in SLH were separated into two groups: before (2009e2011) and after (2012) the program's implementation. Baseline demographics, comorbidities, current medications before treatment, pretreatment National Institute of Health Stroke Scale (NIHSS) total score, actual dose of rtPA (mg/kg of body weight), as well as the treatment outcomes of patients in the two groups, were all retrieved from the stroke registry data. The TSR protocol was approved by the SLH institutional review board before the current study began.
Outcome measures
The main outcome of interest in the current study was DTN time; specifically, the time spent from the patient's arrival to IV bolus injection of rtPA. Other structural outcomes were also selected for comparison: the percentage of DTN time 60 minutes, door-to-CT time, onset-to-needle time, door-to-laboratory time, the percentage of rtPA thrombolysis within 3 hours of onset in all hospitalized patients with AIS who presented within 2 hours of onset (2hr%), and the percentage of rtPA thrombolysis in all hospitalized patients with AIS (AIS%). A modified Rankin scale 8 (mRS) 2 upon discharge was considered the effectiveness outcome, whereas symptomatic ICH (sICH) after rtPA was considered the safety outcome. The presence of sICH is defined following the National Institute of Neurological Diseases and Stroke (NINDS) definition 1 : ICH with deterioration of any neurological symptoms (NIHSS score ! 1) or death.
Statistical analyses
Continuous variables are presented as means AE standard deviation, ordinal or ranked data (e.g., NIHSS) are presented as medians (interquartile range), and categorical data are presented as percentages. To examine the differences in variables between the two groups, two sample t tests were used for continuous variables, and the Pearson c 2 test or Fisher exact test was used for dichotomous variables when indicated. Significance was set at p < 0.05 (two-tailed). Odds ratios (ORs) with 95% confidence intervals (CIs) were used to measure the amplitude of increase in chance before and after the intervention. SAS version 9.2 for Windows (SAS Institute, Cary, NC, USA) was used for all statistical analyses.
Results
We recruited 32 consecutive patients with AIS who had been underwent thrombolytic therapy: 18 patients before and 14 patients after the implementation of the videoassisted thrombolytic program. The actual doses of rtPA that those 32 patients were given were 0.9 AE 0.1 mg/kg of body weight (the recommended dose is 0.9 mg/kg body weight 7 ). Twelve patients (38%) had an mRS score 2 on discharge, whereas 6 patients (19%) had sICH after IV rtPA per NINDS definitions. The baseline characteristics between the two groups of patients, except for the platelet count, were not significantly different (Table 1) .
There was marked improvement in the main outcome (DTN time: 94 AE 24 minutes to 57 AE 14 minutes, p < 0.001) after this program had been initiated ( Table 2 ). The percentage of DTN time 60 minutes improved from 11% to 57% (p Z 0.005; OR: 10.7; 95% CI: 1.7e65.3). The door-to-CT time significantly decreased by an average of 12 minutes, but the door-to-laboratory results time did not significantly change. The AIS% also significantly increased from 2% to 5% (p Z 0.010; OR: 2.5; 95% CI: 1.1e5.4). The 2hr% marginally significantly increased from 18% to 33% (p Z 0.080; OR: 2.2; 95% CI: 0.9e5.3). There were no significant changes in the percentage of mRS scores 2 on discharge or sICH per NINDS definitions.
Discussion
In a typical large-artery ischemic stroke, every 1-minute delay of thrombolysis will lead to the death of 1.9 million neuronal cells, 9 and every 10-minute delay of thrombolysis will decrease one chance of functional independence per Table 1 Baseline characteristics of patients with acute ischemic stroke who received intravenous recombinant tissue-type plasminogen activator treatment before and after the implementation of the video-assisted thrombolytic program.
Characteristics
Before 100 patients treated. 10 The sooner that rtPA is administered during the hyperacute stage of AIS, the greater the likelihood that the patient will be functionally independent after treatment. 11 Despite this known time dependence of rtPA efficacy, fewer than 30% of 25,000 rtPA-treated patients in the US Get With the Guidelines-Stroke (GTWG-Stroke) program were treated with rtPA within 60 minutes after arriving at the hospital. 12 From our observation in clinical practice, it may be difficult to make the patients or their surrogates understand the complex statistics regarding the risks and benefits of rtPA in only a few minutes. Poor understanding of such information about treatment will lead to a time delay in obtaining informed consent.
The results of the current study indicated that a thrombolytic program incorporating a short cartoon video successfully conveyed this type of important information about IV rtPA thrombolytic therapy to patients who needed it. The mean DTN time was 57 minutes and percentage of DTN time 60 minutes was 57% in 2012. The proportion of patients who underwent the treatment also increased from 2% to 5%. Because we choose patients eligible for thrombolytic therapy using the same guidelines before and after the initiation of our video-assisted thrombolytic program, the increase in the overall treatment rate may indicate a better understanding of the benefits related to thrombolytic therapy within 3 hours of symptom onset. Based on previous practice experience, we found that obtaining informed consent was one of the most important steps in thrombolysis. Under the chaotic environment of the emergency department and narrow window for treatment, it is very difficult for physicians to adequately communicate the risk and benefit of rtPA to the patient or family. At one medical center where the time for a brain CT examination and neurologist's evaluation had been minimized, only approximately 6% of patients with AIS who were admitted within 3 hours of stroke onset received rtPA. 13, 14 Failure to obtain informed consent was the reason 21% of the time why potentially eligible AIS patients did not receive rtPA. 14 In addition to shortening of DTN time, our video-assisted informed consent also improved treatment rate. The video we used is now available free of charge on the official website of the Taiwan Stroke Society. Its content has been approved by stroke experts in Taiwan and it can be used at any Taiwan hospital. The use of a video can help physicians to consistently deliver a clear therapeutic risk communication to the patient or family within a very short time. The strategy may be adopted by other hospitals to improve the quality of thrombolytic therapy.
When determining a patient's appropriate rtPA dosage, reliance on an oral statement of body weight from the patient or the surrogate may not be a good practice. Although the patient-or surrogate-reported body weight was not significantly different from the actual body weight measured using a standard scale in the intensive care unit later (63 AE 13 kg vs. 64 AE 13 kg, p Z 0.29), the shortcut did result in small overdoses of the thrombolytic agents (greater than the recommended dose of 0.9 mg/kg body weight 7 ) in 25% of our patients. Fortunately, the overdoses did not increase the risk of sICH per NINDS definition (17% vs. 21% for overdose or not, respectively, p Z 1.00). However, a dosage error because of an inaccurate estimation of body weight reportedly is an independent predictor for a worse outcome after multivariable adjustments according to one German study. 15 Therefore, a new patient bed has been equipped with a scale to correctly and efficiently measure the body weight of stroke patients unable to stand. Body weight can be determined during any of the breaks (waiting for CT or laboratory results, or the arrival of a neurologist).
The posttreatment sICH rates of our patients before and after implementing the video-assisted therapeutic risk communication program were both higher than those reported in the literature. 16, 17 It may be because of our insufficient experience and thrombolytic volume. The complications of IV rtPA increased if the thrombolytic volume of the hospital was less than five treatments per year. 18, 19 Besides, 12 of our 32 patients had comorbidity of chronic kidney disease (CKD), defined as an estimated glomerular filtration rate < 60 mL/min/1.73 m 2 . We found that sICH occurred more frequently in patients with CKD than those without (42% vs. 5%, p Z 0.02). Our findings were in accordance with results of two previous meta-analyses 20,21 that patients with CKD had higher risks of sICH after thrombolytic therapy than those without (ORs: 2.79e3.38). Platelet dysfunction and coagulation abnormality associated with CKD may account for the higher risk for bleeding. 21 Although CKD is not a contraindication for rtPA in the current guideline, 6, 7 further study is warranted about the safety of thrombolytic therapy for stroke patients with CKD in Taiwan. The current study has several limitations. There were many factors affecting the timeliness of thrombolysis, including triage, CT performance, neurological consultation, laboratory support, rtPA administration, and stroke team cooperation. Although the shortening of DTN time from 93 minutes to 57 minutes was greater than the shortening of time to CT or laboratory results, the small sample size and retrospective study design prevented us from directly assessing the effect of video-assisted understanding. Prospective studies with larger samples and control of other factors are needed to test the effectiveness of a thrombolytic program with video-assisted therapeutic risk communication. In addition, the overall treatment results of patients with AIS after they had been treated with thrombolytic therapy in this study were less than satisfactory. Despite the marked decrease of DTN time, we found no improvement in functional outcome presented as mRS scores 2 on discharge (33% vs. 43% before and after the program, respectively, p Z 0.718). This may be because the small sample size of the current study (n Z 32) provided insufficient power to detect any improvement in functional outcome. For example, fewer than 10% of our patients with AIS arrived at the hospital within 3 hours of symptom onset and we performed thrombolytic therapy for AIS only once every 3 months in 2011. Shortening the prehospital delay, both by providing better patient education and by coordinating with the emergency medical service, is required to increase the use of rtPA thrombolytic therapy and improve the outcomes of patients with AIS.
In conclusion, in a community hospital of Taiwan, a thrombolytic program with video-assisted therapeutic risk communication significantly decreased the DTN time and increased the percentage of rtPA thrombolytic therapy in patients with AIS. Additional studies are warranted to test whether such a program would be useful in other settings, such as medical centers, for improving the functional outcome of patients with AIS.
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